2 patients die in Audentes gene therapy study

The San Francisco-based drugmaker stated in a letter June 23 that the clients passed away after experiencing liver problems that appeared to be connected to its speculative drug..

Alia Paavola –
Monday, June 29th, 2020

Ms. Holles said that the company will investigate the 2 deaths thoroughly..

” While this is a dreadful loss and its heartbreaking, we see a course forward here, and were redoubling our efforts as a company to get products to clients as quickly as possible and as broadly as possible, recognizing that we need to do that securely,” Ms. Holles informed STAT.

Audentes CEO Natalie Holles told STAT that the company has stopped registering new patients in the research study, and shortly after the businesss decision, the FDA placed a medical hang on the research study..

X-linked myotubular myopathy is a condition that causes extreme muscle weak point, and most patients with the disorder do not make it through youth.

More posts on drug store: Cheap steroid in scarcity after being posited as possible COVID-19 treatmentRegeneron paid patient charity millions in kickbacks, lawsuit claimsNovartis pays DOJ, SEC $347M in kickback plan settlement.

Two patients in Audentes Therapeutics research study testing a gene therapy for a rare muscle disorder called X-linked myotubular myopathy have actually passed away, according to STAT..

Read the full report here..

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.